Clinical Trials Logo

Clinical Trial Summary

Armodafinil (NuvigilTM) is an isomer of a drug currently approved by the FDA for the treatment of fatigue secondary to narcolepsy, sleep apnea, and shift work sleep disorder called modafinil (ProvigilTM). There is considerable off label evidence for modafinil's ability to reduce fatigue related to multiple sclerosis, Parkinson's disease, cancer related fatigue, and depression related fatigue. There are preclinical studies showing that modafinil can alleviate fatigue secondary to medication side effects (diazepam, chlorpromazine). This multi-layered evidence base suggests that modafinil may be able to alleviate fatigue regardless of medical illness. Armodafinil now has four completed Phase III FDA regulatory studies revealing that it is well tolerated and effective for fatigue associated with obstructive sleep apnea (Effects of Armodafinil in the Treatment of Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome: A 12-Week, Multicenter, Double-Blind, Randomized,Placebo-Controlled Study in nCPAP-Adherent Adults. Thomas Roth et al. Clinical Therapeutics/Volume 28, Number 5, 2006), shift work sleep disorder, and narcolepsy. Armodafinil is not yet FDA approved. It is felt to be a cleaner, safer, more potent isomer. Theoretically, fatigue is interpreted and possibly dictated centrally and armodafinil's proposed mechanism (similar to that of modafinil) of elevating central histamine activity may allow the brain to interpret a lower fatigue state, thus allowing patients to function better during the day with less peripheral fatigue.

Fibromyalgia (FM) is an illness that may involve medical, rheumatological, autoimmune, sleep, endocrine and psychiatric pathology. It is a syndrome of recurrent pain at trigger points. Greater than 90% of these patients will report fatigue as a key symptom as well. There are several investigation lines into the treatment of FM induced pain. Exercise, behavioral therapy, amitryptiline, duloxetine, tramadol, sodium oxybate all have randomized trials and almost all focus on pain. There are very few studies, if any, that look at FM induced fatigue which certainly ads to FM patients' daily incapacity and lowered productivity/quality of life.

Armodafinil is a drug with minimal adverse effects (headache, insomnia, GI distress, anxiety, dry mouth, dizziness and an assumed low level addiction which is comparable to modafinil) which is well tolerated in current regulatory studies. It may have a safer tolerability profile than the FM medications noted above. As modafinil is often studied and often added as an augmentation agent to patients' regimens who suffer from fatigue in other medical illnesses, the authors feel that armodafinil would also be effective in this population. The authors wish to conduct a study to determine if armodafinil is safe and tolerable in the treatment of FM induced fatigue. This initial controlled study may allow for continued regulatory studies with this product in FM subjects. We propose a double-blind placebo controlled study to determine if armodafinil is safe and effective in reversing FM induced fatigue.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00678691
Study type Interventional
Source State University of New York - Upstate Medical University
Contact
Status Completed
Phase Phase 4
Start date August 2007
Completion date December 2009

See also
  Status Clinical Trial Phase
Completed NCT03149198 - Mat Pilates Method in the Treatment of Women With Fibromyalgia N/A
Completed NCT00965081 - A Study for Adult Patients With Fibromyalgia Phase 4
Enrolling by invitation NCT06100926 - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain N/A
Recruiting NCT05068791 - Psilocybin-facilitated Treatment for Chronic Pain Early Phase 1
Recruiting NCT05801497 - Balneotherapy in Primary Fibromyalgia
Active, not recruiting NCT04422522 - Fibromyalgia During the COVID-19 Pandemic
Completed NCT05361577 - Exopulse Mollii Suit and Fibromyalgia N/A
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT05941780 - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Completed NCT04771260 - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting NCT04690400 - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic N/A
Recruiting NCT05644054 - The Impact of THC on Pain Modulation in Fibromyalgia N/A
Enrolling by invitation NCT04098757 - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed NCT01697254 - The CARRA Registry N/A
Recruiting NCT04832100 - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting NCT05688787 - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia N/A
Completed NCT03905486 - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia. N/A